サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1561639

3Dバイオプリンティング市場レポート：コンポーネント、用途、エンドユーザー、地域別、2024年～2032年

3D Bioprinting Market Report by Component (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
3Dバイオプリンティング市場レポート：コンポーネント、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年09月10日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

3Dバイオプリンティング市場の世界市場規模は、2023年に12億580万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに42億8,190万米ドルに達し、2024年から2032年の間に14.7%の成長率（CAGR）を示すと予測しています。高齢者人口の増加、研究開発（R&D）活動への注力の高まり、市場破壊の少なさなどが市場成長を促進する主な要因です。

3Dバイオプリンティング市場分析：

  • 主な市場促進要因：個別化医療における3Dバイオプリンティングの利用拡大が、主に市場成長の原動力となっています。3Dバイオプリンティングは、患者固有の組織や臓器を作成することができ、個別化された治療計画を可能にし、移植拒絶反応のリスクを低減します。
  • 主な市場動向：精密な形状と生物学的機能性を備えた複雑な生物医学デバイスやインプラントを製造するためにバイオプリンティングの利用が拡大していることは、市場の成長を促進する重要な動向の1つです。さらに、生体材料や印刷技術の改良など、3Dバイオプリンティング技術の急速な進歩も市場拡大に寄与しています。
  • 競合情勢：世界市場で事業を展開する大手企業には、3D Systems Inc.、Aspect Biosystems Ltd.、Cellink、Cyfuse Biomedical K.K.、EnvisionTEC GmbH（Desktop Metal Inc.）、GeSiM-Gesellschaft fur Silizium-Mikrosysteme mbH、Materialise、Organovo Holdings Inc.、Poietis、RegenHU、Stratasys Ltd.などがあります。
  • 地域情勢別：報告書によると、北米（米国とカナダ）が3Dバイオプリンティングの最大市場です。北米の3Dバイオプリンティング市場を牽引する要因としては、さまざまな慢性疾患の有病率の増加、主要プレイヤーの幅広い存在感、民間および政府投資の増加などが挙げられます。
  • 課題と機会：世界の3Dバイオプリンティング市場は、高コスト、技術的複雑性、規制上のハードルなどの課題に直面しています。しかし、革新的な組織工学ソリューションを通じて、個別化医療の進展、薬物検査精度の向上、臓器移植不足への対応などの機会がもたらされます。

3Dバイオプリンティング市場傾向：

薬剤検査と開発の増加

3Dバイオプリンターは、薬物検査と臨床試験アプリケーションにとって非常に重要です。3Dバイオプリンターは、動物実験の必要性を大幅に削減し、倫理的に有益で費用対効果が高いと期待されています。3Dバイオプリンティングの出現により、医薬品開発者は、ヒトに似た3Dプリント組織で新薬を試験することで、ヒト臨床試験に関連する合併症を容易に特定することができ、後期段階の失敗による損失を減らすことができます。さらに、企業による研究開発への投資の増加は、3Dバイオプリンティングのような革新的技術への需要をさらにエスカレートさせています。例えば、米国議会予算局が発表したデータによると、2021年、製薬業界は2020年の研究開発に世界全体で約2,000億米ドルを投じたのに対し、2019年には8,300万米ドルを投じたことが確認されています。同様に、Danaher Corporationは、2020年の13億4,800万米ドルに対し、2021年には17億4,200万米ドルを研究開発に投資しました。また、バイオ・ラッド・ラボラトリーズ・インクは、2020年の8億30万米ドルに対し、2021年には8億7,960万米ドルを投資しました。このような治験や医薬品開発への多額の投資は、今後数年間の3Dバイオプリンティング市場の規模を押し上げると予想されます。

技術的進歩

3Dバイオプリンティングの継続的な技術進歩は、市場全体に有利な成長機会をさらに提供しています。さらに、さまざまな大手市場開拓企業が、より先進的で効率的な3Dバイオプリンティング技術を開発するために提携や協力関係を結んでいます。例えば、2024年6月、先進的組織模倣技術企業のRonawk社は、B9Creations社と提携し、Ronawk社のBio-Blocksを活用した3Dバイオプリントハイドロゲルの開発と量産を開始しました。細胞を人工的な環境に強制的に置く従来の方法とは異なり、RonawkのBio-Blockは細胞が自然に組織を形成できる条件を再現します。その結果、人間や動物の組織が本来持っている構造と機能に酷似した組織ができます。同様に、2022年9月、インド科学研究所（IISc）は、スウェーデンに本拠を置くバイオプリンティング・ソリューション企業であるCELLINK社との提携を発表し、センター・オブ・エクセレンス（CoE）に2～3台のバイオプリンターを提供することを明らかにしました。さらに、2022年12月、CELLINKとIIScは共同で、インドにおけるベンガルールの先駆的な3Dバイオプリンティング・センター・オブ・エクセレンスを設立しました。3Dバイオプリンティングにおけるこのような技術革新、提携、拡大は、予測期間中、3Dバイオプリンティング市場の見通しにプラスの影響を与えると予測されます。

がん研究における製品用途の拡大

3Dバイオプリンティングは、実際のヒト腫瘍の複雑さや微小環境を忠実に模倣したリアルな腫瘍モデルの作成に広く利用されています。これらのバイオプリントモデルにより、研究者は制御された環境でがんの進行、転移、腫瘍-間質相互作用を研究することができます。さらに、世界中でがん患者が増加していることが、市場全体に有利な成長機会をもたらしています。例えば、国際がん研究機関（IARC）は、2020年には約1,929万人のがん患者が発生すると推定しています。これらの症例は、2030年までに2,458万症例まで増加すると予測されています。また、GLOBOCANによると、2020年には米国だけで新たにがんと診断された症例は約228万1,658人、がんが原因で死亡した症例は61万2,390人です。これに加えて、肺がんと乳がんは、個人の間で最もよく見られるがんの2つです。カナダがん協会（CCS）は、2020年には約2万9,800人のカナダ人が肺がんと診断され、新たながん患者の13％を占めると述べた。約21,200人のカナダ人が肺がんで死亡すると予想され、これは2020年のがん死亡者全体の25％を占める。がん患者のこのような大幅な増加は、効果的な治療法を特定し、薬剤耐性メカニズムを理解し、がん治療を個別化するのに役立つ3Dバイオプリンティング技術の需要を増大させています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の3Dバイオプリンティング市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：コンポーネント別

  • 3Dバイオプリンター
    • 市場動向
    • 主要セグメント
      • シリンジ/押し出しバイオプリンティング
      • インクジェットバイオプリンティング
      • 磁気浮上バイオプリンティング
      • レーザーアシストバイオプリンティング
      • その他
    • 市場予測
  • 足場
    • 市場動向
    • 市場予測
  • 生体材料
    • 市場動向
    • 主要セグメント
      • 生きた細胞
      • ハイドロゲル
      • 細胞外マトリックス
      • その他
    • 市場予測

第7章 市場内訳：用途別

  • 研究
    • 市場動向
    • 主要セグメント
      • 医薬品調査
      • 再生医療
      • 3D細胞培養
    • 市場予測
  • 臨床
    • 市場動向
    • 主要セグメント
      • 肌
      • 骨と軟骨
      • 血管
      • その他
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 研究機関および学術機関
    • 市場動向
    • 市場予測
  • バイオ医薬品企業
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • 3D Systems Inc.
    • Aspect Biosystems Ltd.
    • Cellink
    • Cyfuse Biomedical K.K.
    • EnvisionTEC GmbH（Desktop Metal Inc.）
    • GeSiM-Gesellschaft fur Silizium-Mikrosysteme mbH
    • Materialise
    • Organovo Holdings Inc.
    • Poietis
    • RegenHU
    • Stratasys Ltd.
図表

List of Figures

  • Figure 1: Global: 3D Bioprinting Market: Major Drivers and Challenges
  • Figure 2: Global: 3D Bioprinting Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: 3D Bioprinting Market: Breakup by Component (in %), 2023
  • Figure 5: Global: 3D Bioprinting Market: Breakup by Application (in %), 2023
  • Figure 6: Global: 3D Bioprinting Market: Breakup by End User (in %), 2023
  • Figure 7: Global: 3D Bioprinting Market: Breakup by Region (in %), 2023
  • Figure 8: Global: 3D Bioprinting (3D Bioprinters) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: 3D Bioprinting (3D Bioprinters) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: 3D Bioprinting (Scaffolds) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: 3D Bioprinting (Scaffolds) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: 3D Bioprinting (Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: 3D Bioprinting (Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: 3D Bioprinting (Research) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: 3D Bioprinting (Research) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: 3D Bioprinting (Clinical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: 3D Bioprinting (Clinical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: 3D Bioprinting (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: 3D Bioprinting (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: 3D Bioprinting (Research Organization and Academic Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: 3D Bioprinting (Research Organization and Academic Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: 3D Bioprinting (Biopharmaceuticals Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: 3D Bioprinting (Biopharmaceuticals Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: North America: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: North America: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: United States: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: United States: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Canada: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Canada: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Asia-Pacific: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Asia-Pacific: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: China: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: China: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Japan: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Japan: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: India: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: India: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: South Korea: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: South Korea: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Australia: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Australia: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Indonesia: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Indonesia: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Others: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Others: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Europe: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Europe: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Germany: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Germany: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: France: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: France: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United Kingdom: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United Kingdom: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Italy: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Italy: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Spain: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Spain: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Russia: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Russia: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Latin America: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Latin America: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Brazil: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Brazil: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Mexico: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Mexico: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Middle East and Africa: 3D Bioprinting Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Middle East and Africa: 3D Bioprinting Market: Breakup by Country (in %), 2023
  • Figure 72: Middle East and Africa: 3D Bioprinting Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: 3D Bioprinting Industry: SWOT Analysis
  • Figure 74: Global: 3D Bioprinting Industry: Value Chain Analysis
  • Figure 75: Global: 3D Bioprinting Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: 3D Bioprinting Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: 3D Bioprinting Market Forecast: Breakup by Component (in Million US$), 2024-2032
  • Table 3: Global: 3D Bioprinting Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: 3D Bioprinting Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: 3D Bioprinting Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: 3D Bioprinting Market: Competitive Structure
  • Table 7: Global: 3D Bioprinting Market: Key Players
目次
Product Code: SR112024A4556

The global 3D bioprinting market size reached US$ 1,205.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 4,281.9 Million by 2032, exhibiting a growth rate (CAGR) of 14.7% during 2024-2032. The growing geriatric population, increasing focus on research and development (R&D) activities, and less disrupted market represent some of the key factors driving the market growth.

3D Bioprinting Market Analysis:

  • Major Market Drivers: The increasing utilization of 3D bioprinting in personalized medicine is primarily driving the growth of the market. 3D bioprinting can create patient-specific tissues and organs, enabling personalized treatment plans and reducing the risk of transplant rejection.
  • Key Market Trends: The escalating utilization of bioprinting to manufacture complex biomedical devices and implants with precise geometries and biological functionalities is one of the significant trends driving the growth of the market. Furthermore, rapid advancements in 3D bioprinting technology, including improved biomaterials and printing techniques, are also contributing to the market expansion.
  • Competitive Landscape: Some of the leading players operating in the global market include 3D Systems Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH, Materialise, Organovo Holdings Inc., Poietis, RegenHU, and Stratasys Ltd., among others.
  • Geographical Landscape: According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting. Some of the factors driving the North American 3D bioprinting market include the growing prevalence of various chronic diseases, the wide presence of key players, and increasing private and government investment.
  • Challenges and Opportunities: The global 3D bioprinting market faces challenges such as high costs, technical complexities, and regulatory hurdles. However, it presents opportunities to advance personalized medicine, improve drug testing accuracy, and address organ transplant shortages through innovative tissue engineering solutions.

3D Bioprinting Market Trends:

Increasing Drug Testing and Development

3D bioprinters are highly important for drug testing and clinical trial applications. They are expected to drastically reduce the need for animal trials, thus being ethically beneficial and cost-effective. With the advent of 3D bioprinting, drug developers can easily identify complications associated with human clinical trials by testing new drugs on human-like 3D-printed tissues, thereby reducing losses from late-stage failures. Additionally, the increasing investment in research and development by the companies is further escalating the demand for innovative technologies like 3D bioprinting. For instance, according to the data published by the Congressional Budget Office, in 2021, it has been observed that pharmaceutical industries spent nearly US$ 200 Billion on research and development in 2020 globally compared to US$ 83 Million in 2019. Similarly, Danaher Corporation invested US$ 1,742 Million in its research and development in 2021, as compared to US$ 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc. invested US$ 879.6 Million in 2021 as compared to US$ 800.3 Million in 2020. Such significant investments in drug trials and drug development are anticipated to propel the 3D bioprinting market size in the coming years.

Technological Advancements

Ongoing technological advancements in 3D bioprinting are further offering lucrative growth opportunities to the overall market. Additionally, various leading market players are collaborating and forming partnerships to develop more advanced and efficient 3D bioprinting technologies. For instance, in June 2024, advanced tissue mimetic technologies company Ronawk partnered with B9Creations to develop and mass-produce 3D bioprinted hydrogels leveraging Ronawk's Bio-Blocks. Unlike traditional methods that force cells into artificial environments, Ronawk's Bio-Blocks recreate conditions that allow cells to form tissues naturally. This results in tissue that closely resembles the native architecture and function of human and animal tissues. Similarly, in September 2022, the Indian Institute of Science (IISc) announced its collaboration with CELLINK, a Sweden-based bioprinting solutions company, to provide two to three bioprinters to the Centre of Excellence (CoE), each of which uses a different printing technology at its own cost. Additionally, in December 2022, CELLINK and IISc jointly established Bengaluru's pioneering 3D Bioprinting Centre of Excellence in India. Such innovations, collaborations, and expansion in 3D bioprinting are projected to positively impact the 3D bioprinting market outlook over the forecasted period.

Growing Product Application in Cancer Research

3D bioprinting is widely used in the creation of realistic tumor models that closely mimic the complexity and microenvironment of actual human tumors. These bioprinted models enable researchers to study cancer progression, metastasis, and tumor-stroma interactions in a controlled setting. Moreover, the escalating cases of cancer across the globe are further offering lucrative growth opportunities to the overall market. For instance, the International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Additionally, according to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. Such a substantial growth in cancer cases is augmenting the demand for 3D bioprinting technologies that help identify effective treatments, understand drug resistance mechanisms, and personalize cancer therapies.

Global 3D Bioprinting Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global 3D bioprinting market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on component, application, and end user.

Component Insights:

  • 3D Bioprinters
    • Syringe/Extrusion Bioprinting
    • Inkjet Bioprinting
    • Magnetic Levitation Bioprinting
    • Laser-assisted Bioprinting
    • Others
  • Scaffolds
  • Biomaterials
    • Living Cells
    • Hydrogels
    • Extracellular Matrices
    • Others

3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment

The 3D bioprinting market research report has provided a detailed breakup and analysis of the 3D bioprinting market based on the component. This includes 3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others). According to the report, 3D bioprinters (syringe or extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment.

The bolstering demand for 3D bioprinters can be attributed to the increasing utilization of syringe or extrusion-based bioprinting technology in printing various biological compounds or devices. They are widely used in fabricating tissue scaffolds for regenerative medicine, developing organ models for transplant research, and creating realistic tissue models for drug testing and cancer research. Moreover, 3D bioprinters have the ability to produce complex, customized biological structures, improve the accuracy of drug testing, and reduce the need for animal testing. As a result, they are widely used in the fields of tissue engineering, personalized medicine, pharmaceutical development, and medical research.

Application Insights:

  • Research
    • Drug Research
    • Regenerative Medicine
    • 3D Cell Culture
  • Clinical
    • Skin
    • Bone and Cartilage
    • Blood Vessels
    • Others

Research (drug research, regenerative medicine, and 3D cell culture) accounted for the largest market share

A detailed breakup and analysis of the 3D bioprinting market based on the application has also been provided in the report. This includes research (drug research, regenerative medicine, and 3D cell culture) and clinical (skin, bone and cartilage, blood vessels, and others). According to the report, research (drug research, regenerative medicine, and 3D cell culture) accounted for the largest market share.

The growth of this segment can be attributed to the widespread utilization of 3D printing technology among researchers to study the effects of different diseases and their progression and possible treatments. Moreover, it reduces the need to use lab animals for medical tests and dangerous trials on humans. Additionally, the 3D bioprinting market forecast by IMARC indicates that the increasing drug development and drug trial activities are bolstering the application of 3D bioprinting in research. For instance, with the COVID-19 pandemic behind, the US Food and Drug Administration (FDA) approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best yearly FDA harvest after 2018 (59 approvals) in all the series. Such a significant growth in drug trials and approval is creating a positive outlook for the overall market.

End User Insights:

  • Hospitals
  • Research Organization and Academic Institutes
  • Biopharmaceuticals Companies

Biopharmaceuticals companies accounted for the largest market share

A detailed breakup and analysis of the 3D bioprinting market based on the end user has also been provided in the report. This includes hospitals, research organization and academic institutes, and biopharmaceuticals companies. According to the report, biopharmaceuticals companies accounted for the largest market share.

The 3D bioprinting market statistics by IMARC indicate that the increasing number of target therapies is primarily driving the growth of this segment. In addition to this, the rising collaborations and mergers and acquisition activities among biopharmaceutical companies to develop 3D bioprinting are positively influencing the market. For instance, in June 2022, REGEMAT 3D, a company at the forefront of personalized bio fabrication solutions, announced a partnership with Humabiologics, a company providing human-derived biomaterials for regenerative medicine, in response to the growing demand and to serve a broader life sciences customer base of the industry partners and academic institutions in the European bioprinting and drug testing market.

Regional Insights:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America (the United States and Canada) was the largest market for 3D bioprinting

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting.

Some of the factors driving the North American 3D bioprinting market included the growing prevalence of various chronic diseases, the presence of key players, and increasing private and government investments. Additionally, new product launches by the key market players in the region, along with the easy allocation of funds to conduct R&D activities, are further creating a positive outlook for the overall market. For instance, in 2022, scientists from Florida Atlantic University and the University of Virginia created a robotic model of the human spine to assist surgeons in anticipating the outcomes of interventions before surgery. Thus, the increasing demand for 3D bioprinting for healthcare physicians is expected to boost the market over the forecast period. Additionally, the rising investments by the regional government authorities in the healthcare sector are projected to propel the 3D bioprinting market share in the coming years.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global 3D bioprinting market. Some of the companies covered in the report include:

  • 3D Systems Inc.
  • Aspect Biosystems Ltd.
  • Cellink
  • Cyfuse Biomedical K.K.
  • EnvisionTEC GmbH (Desktop Metal Inc.)
  • GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH
  • Materialise
  • Organovo Holdings Inc.
  • Poietis
  • RegenHU
  • Stratasys Ltd.

(Please note that this only represents a partial list of companies, and the complete list has been provided in the report.)

Global 3D Bioprinting Market News:

  • June 2024: Advanced tissue mimetic technologies company Ronawk partnered with B9Creations to develop and mass-produce 3D bio-printed hydrogels leveraging Ronawk's Bio-Blocks.
  • February 2024: Nanavati Max Super Specialty Hospital in Mumbai, India, launched a medical 3D printing laboratory to facilitate high-precision surgeries. The facility is closely integrated with oncology to enable state-of-the-art surgeries that need to be performed carefully and accurately in oncologic, reconstructive orthopedic, and specialized dentistry surgeries. The 3D printing laboratory features two 3D printers capable of producing bone models for a better understanding of intricate anatomy or pathology.

Key Questions Answered in This Report

  • 1. What was the size of the global 3D bioprinting market in 2023?
  • 2. What is the expected growth rate of the global 3D bioprinting market during 2024-2032?
  • 3. What are the key factors driving the global 3D bioprinting market?
  • 4. What has been the impact of COVID-19 on the global 3D bioprinting market?
  • 5. What is the breakup of the global 3D bioprinting market based on the component?
  • 6. What is the breakup of the global 3D bioprinting market based on the application?
  • 7. What is the breakup of the global 3D bioprinting market based on the end user?
  • 8. What are the key regions in the global 3D bioprinting market?
  • 9. Who are the key players/companies in the global 3D bioprinting market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global 3D Bioprinting Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 3D Bioprinters
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Syringe/Extrusion Bioprinting
      • 6.1.2.2 Inkjet Bioprinting
      • 6.1.2.3 Magnetic Levitation Bioprinting
      • 6.1.2.4 Laser-assisted Bioprinting
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Scaffolds
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Biomaterials
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Living Cells
      • 6.3.2.2 Hydrogels
      • 6.3.2.3 Extracellular Matrices
      • 6.3.2.4 Others
    • 6.3.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Research
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Drug Research
      • 7.1.2.2 Regenerative Medicine
      • 7.1.2.3 3D Cell Culture
    • 7.1.3 Market Forecast
  • 7.2 Clinical
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Skin
      • 7.2.2.2 Bone and Cartilage
      • 7.2.2.3 Blood Vessels
      • 7.2.2.4 Others
    • 7.2.3 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Organization and Academic Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Biopharmaceuticals Companies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 3D Systems Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Aspect Biosystems Ltd.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Cellink
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Cyfuse Biomedical K.K.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 EnvisionTEC GmbH (Desktop Metal Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Materialise
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Organovo Holdings Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Poietis
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 RegenHU
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Stratasys Ltd.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials